drugset
drugset / Trial / NCT04720443

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

NCT04720443 ↗

Phase 1 Completed 56 enrolled The National Institutes of Pharmaceutical R&D Co. Ltd, China
RandomizedSequentialDouble-blindTreatment

Summary

This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.

Timeline

Start
2019-11-22
Primary completion
2022-07-14
Completion
2022-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject NIP292 Unknown 10 mg Oral
Subject NIP292 Unknown 30 mg Oral
Subject NIP292 Unknown 100 mg Oral
Subject NIP292 Unknown 300 mg Oral
Subject NIP292 Unknown 500 mg Oral

Indications

idiopathic pulmonary fibrosis